Segment Reporting

6 Months Ended

Jun. 30, 2023

Segment Reporting [Abstract]

Segment Reporting

13.   Segment Reporting. We report our operations in two operating segments: cardiovascular and endoscopy. Our cardiovascular segment consists of four product categories: peripheral intervention, cardiac intervention, custom procedural solutions, and OEM. Within these product categories, we sell a variety of products, including cardiology and radiology devices (which assist in diagnosing and treating coronary arterial disease, peripheral vascular disease and other non-vascular diseases), as well as embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, breast cancer localization and guidance, biopsy, and interventional oncology and spine devices. Our endoscopy segment consists of gastroenterology and pulmonology devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. We evaluate the performance of our operating segments based on net sales and income from operations.

Financial information relating to our reportable operating segments and reconciliations to the consolidated totals for the three and six-month periods ended June 30, 2023 and 2022, were as follows (in thousands):

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2023		2022		2023		2022
Net sales
Cardiovascular	$	311,275	$	286,670	$	599,251	$	553,606
Endoscopy		8,781		8,306		18,370		16,785
Total net sales		320,056		294,976		617,621		570,391
Income from operations
Cardiovascular		26,464		21,275		50,398		34,401
Endoscopy		2,348		1,981		4,797		4,088
Total income from operations		28,812		23,256		55,195		38,489
Total other expense — net		(3,912)		(2,555)		(4,795)		(3,617)
Income tax expense		4,655		5,403		9,452		9,029
Net income	$	20,245	$	15,298	$	40,948	$	25,843